Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases

Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1999, Pages 366-372

  El Yazigi, Adnan ^a   Shabib, Souheil ^a   Al Rawithi, Sameer ^a   Yusuf, Ahmed ^a   Legayada, Erlinda S ^a   Al Humidan, Abdulkarim ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450; XANTHINE OXIDASE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SALIVA LEVEL; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER DISEASE; LIVER FUNCTION; MALE; ORAL DRUG ADMINISTRATION; URINALYSIS;

EID: 0040066722     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007930     Document Type: Article

References (32)

1. Weidner G, Istvan J: Dietary sources of caffeine. NEJM 1985;313:1421.
2. Bunker ML, McWilliams M: Caffeine content of common beverages. J Am Diet Assoc 1979;74:28-32.
3. Lewis FW, Rector WG: Caffeine clearance in cirrhosis: the value of simplified determinations of liver metabolic capacity. J Hepatol 1992;14:157-162.
4. Hamelin BA, Xu K, Valle F, Manseau L, Richer M, LeBel M: Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994;56:521-529.
5. Rost KL, Roots I: Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-411.
6. Varagnolo M, Plebani M, Mussap M, Nemetz L, Paleari CD, Burlina A: Caffeine as an indicator of metabolic functions of microsomal liver enzymes. Clinica Chemica Acta 1989;183:91-94.
7. Bianchetti MG, Kraemer R, Passweg J, Jost J, Preisig R: Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. J Pediatr Castro and Nutr 1988;7:688-693.
8. Soto J, Sacristan JA, Alsar MJ: Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism. Ann Pharmacother 1996;30:736-739.
9. Blancharad J, Sawers SJA: The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983;24:93-98.
10. Grant DM, Tang BK, Kalow W: Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983;33:355-359.
11. Grant DM, Tang BK, Kalow W: Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
12. Grant DM, Tang BK, Kalow W: A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-464.
13. El-Yazigi A, Chaleby K, Martin CR: Simplified and rapid test for acetylator phenotyping by use of the peak height ratio of two urinary caffeine metabolites. Clin Chem 1989;35:848-851.
14. Ullrich D, Compagnone D, Munch B, Brandes A, Hille H, Bircher J: Urinary caffeine metabolites in man: age-dependent changes and pattern in various clinical situations. Eur J Clin Pharmacol 1992;43:167-172.
15. 2 breath test: dose response and route of N-demethylation in smokers and non-smokers. Clin Pharmacol Ther 1982;32:261-269.
16. Bircher J: Quantitative assessment of deranged hepatic function: a missed opportunity? Sem Liver Disease 1983;3:275-284.
17. Wahllander A, Mohr S, Paumgartner G: Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1990;10:129-137.
18. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R: Caffeine: a model compound for measuring liver function. Hepatol 1984;4:38-46.
19. Desmond PV, Patwardhan RV, Johnson RF, Schenker S: Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 1980;25:193-197.
20. Campbell ME, Spielberg SP, Kalow W: A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-165.
21. Bosso JA, Liu Q, Evans WE, Relling MV: CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Pharmacother 1996;16:749-753.
22. Rasmussen BB, Brosen K: Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996;18:254-262.
23. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW: Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995;39:65-69.
24. Wietholtz H, Zysset T, Marschall H-U, Generet K, Matern S: The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995;22:78-81.
25. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450PA (P4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-7700.
26. Fuhr U, Rost KL: Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenet 1994;4:109-116.
27. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenet 1992;2:116-127.
28. Clark DWJ: Genetically determined variability in acetylation and oxidation: therapeutic implication. Drugs 1985;29:342-375.
29. El-Yazigi A, Johansen K, Raines DA, Dosing M: N-acetylation polymorphism and diabetes mellitus among Saudi Arabians. J Clin Pharmacol 1992;32:905-910.
30. Boda D, Nemeth I: Measurement of urinary caffeine metabolites reflecting the "in vivo" xanthine oxidase activity in premature infants with RDS and in hypoxic states of children. Biomed Biochem Acta 1989;48:S31-S35.
31. Parks DA, Granger DN: Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand 1986;S548:87-99.
32. Kato M, Morikawa A, Kimura H, Shimizu T, Nakano M, Kuroume T: Effects of antiasthma drugs on superoxide anion generation from human polymorphonuclear leukocytes or hypoxanthine-xanthine oxidase systems. Int Arch Allergy Appl Immunol 1991;96:128-133.